Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

und RG7227 (ITMN-191) which entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon this data, in combination with the other efficacy and safety results the company currently has submitted in support of its NDA file and plans to submit in support of its MAA filing. Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly fol
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Pipeline Review, 2015 market research report that provides ... pipeline stage using data sourced from in-house databases, ... on syringes and needles market products pipeline spread ... organizations supported with 73 tables and 5 figures ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 53D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
(Date:8/1/2015)... ... , ... “ reTXT ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... and delete any message including ones already sent. , While text messaging has more ...
(Date:7/31/2015)... NV (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source ... at the MGM Grand Garden Arena. Fans of every genre of music will have ... September 18th, the first day of the festival, the following artists will perform: Sam ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... New research from the Howard Florey Institute in Melbourne ... cause epilepsy in infants. , Infants are more susceptible ... rapid rate, making their brain cells excitable. Their neurons ... cells, which can disrupt normal brain activity and results ...
... discovery made 25 years ago about how the brain ... with the help of scientists from the Howard Florey ... in Melbourne this month to collaborate with Florey scientists, ... research involving a pathway in the brain that controls ...
... Rep and New VP, SAINT PETERSBURG, Fla., ... the bywords for Florida,s fastest growing medical,manufacturer. Ultroid ... of the Ultroid Hemorrhoid Management System has,announced an ... As one of the nation,s most respected ...
... Fervent Support for ... Party, CHICAGO, Oct. 3 /PRNewswire-USNewswire/-- Americans may be sharply,divided ... the United States,but they are in strong agreement when it ... a nationwide trauma system. According to results,of the American College ...
... Facility, AHF,s First in Kenya, is US AIDS Group,s ... Worldwide. New Kenyan Partnership Will, Provide Life- saving Anti-retroviral ... Kenya, where the National HIV/AIDS ... ANGELES, Oct. 3 AIDS,Healthcare Foundation (AHF), has joined ...
... Calif., Oct. 3 Thermage, Inc.,(Nasdaq: THRM ... distribution agreement,with Eclipse Medical, Ltd., a leading distributor ... the new agreement,Eclipse sales professionals will market the ... region of the United States. "We are ...
Cached Medicine News:Health News:Research shows how genetic mutation causes epilepsy in infants 2Health News:New Ties Support Ultroid's Upward Mobility 2Health News:A Nation Divided Over Health Care? Not So Fast 2Health News:A Nation Divided Over Health Care? Not So Fast 3Health News:AHF and Kenya Medical Research Institute Partner to Save Lives at Free AIDS Treatment Clinic in Mombasa 2Health News:AHF and Kenya Medical Research Institute Partner to Save Lives at Free AIDS Treatment Clinic in Mombasa 3Health News:Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd. 2
... Tissue Anchor allows one step fixation of soft ... arthroscopic knotless rotator cuff repair in one simple ... outside thread diameter of 5 mm and a ... suspension sutures securely hold a thin, bioabsorbable PLLA ...
... are also available for use when performing mini-open ... comes with a 26 mm 1/2 circle, tapered ... door on the inserter handle.,The punch is used ... is inserted. In hard bone, the tap or ...
... can be used as an adjunct to ... apposition to bone to speed healing and ... fixation forces over a greater area dramatically ... mm thick disc of bioabsorbable PLLA has ...
... a new generation of polyester suture with ... greater strength than similar sized polyester suture ... lower knot profile. FiberWire is the ideal ... virtually eliminating suture breakage during knot tying.,All ...
Medicine Products: